Cost of Illness Analysis of Insulin and Insulin-Metformin Combination Usage towards Diabetes Mellitus Type 2 Patients at Hospital in Bandung

Abstract

Diabetes mellitus (DM) type 2 is a progressive disease that impact on the patients incurred costs during the illness. This study was conducted on May to June at one of hospital in Bandung. This study aimed to obtain cost of illness calculation of insulin monotherapy and insulin-metformin combination in patients with type 2 diabetes using Cost of Illness analysis (COI). This study used cross-sectional method with retrospective data collection on outpatients with 6 months therapy period in 2013. The cost of the measured components are direct medical costs (the cost of doctor visits, medicine costs, costs of complications and the cost of laboratories test) and human capital (HC) such as indirect non-medical costs (lost revenue per day). The results show the value of COI in the six months treatment of insulin and insulin-metformin combination sequentially 661,063.59 IDR and 443,165.28 IDR. This study shows that the use of combination therapy of insulin-metformin has lower cost of illness compared with insulin monotherapy and statistically (student t-test) showed significant differences p=0.004 (p<0.05).